Oncomed Pharma Says Phase 1B Study Of Tarextumab Shows Changes IN CTCS That Appear To Correlate With  OS Outocmes, ANTI-RSPO3 With Paclitaxel Chemo Showed Synergistic Anti-Tumor Activity IN Tumors With RSPO3 Tanslocations